Finvest
LH Healthcare services · Clinical labs · Diagnostics · Biopharma services · Thesis updated June 13, 2026

Margins are improving, but BLS is slowing

01 Running thesis

Execution is better, growth is less clear

Labcorp is showing better operating discipline. In Q1 2026, Diagnostics margin rose 30 basis points to 16.6%. Biopharma Laboratory Services margin rose 60 basis points to 15.5%. That matters because small margin gains can move earnings in a lab business with large fixed costs.

The bull case is simple: keep testing volumes growing, fold in acquisitions well, and let the lab network do more work without costs rising as fast. The Invitae acquisition had hurt Diagnostics margins earlier, but recent filings show the larger segment has moved back to margin expansion.

The bear case is also clear. Biopharma Laboratory Services, or BLS, is still growing, but its organic growth has slowed for several quarters. It was 5.3% in Q3 2025, 4.0% in Q4 2025, and 3.7% in Q1 2026. That raises the risk that drugmaker research demand is cooling.

This is a balanced setup, not a one-way story. The biggest things to watch over the next year are the Ravgen appeal, whether BLS growth bottoms, and whether both segments can keep margins near current levels.

May 2026→Q1 2026 showed more margin expansion in both segments, which supports the execution story. BLS organic growth slowed again to 3.7%, keeping the overall view balanced.
Feb 2026▲The 2025 annual filing improved the risk profile because PAMA cuts were delayed and the FDA LDT rule was rescinded. The same filing also made the Ravgen patent case a central risk.
Oct 2025▲Q3 2025 weakened the old margin-pressure bear case as Diagnostics margin expanded 110 basis points year over year. BLS growth slowed, but the profit trend improved.
Aug 2025▲Q2 2025 marked a profit inflection, with Diagnostics margin expanding after earlier pressure. BLS also grew well, though new healthcare funding uncertainty was noted.
Apr 2025→Q1 2025 kept the thesis mixed. Diagnostics revenue grew, but margin fell, while BLS margin improved on demand and cost savings.
Feb 2025▼The 2024 annual filing showed strong BLS margin progress but weaker Diagnostics margin. It also added clearer 2026 risk from PAMA cuts and the FDA LDT rule.
Oct 2024→The initial post-Fortrea view centered on two segments: Diagnostics and BLS. Growth looked steady, but acquisitions were pressuring margins in the larger Diagnostics business.
02 Business model

Paid per test and per lab service

Labcorp makes money by charging for lab work. In Diagnostics, it runs clinical tests ordered by doctors and paid for by insurers, government programs, patients, and healthcare providers. In BLS, it sells lab services to drug companies that need support while developing new medicines.

The model has scale benefits. Once Labcorp has the lab network, equipment, couriers, and systems in place, added volume can carry good profit if pricing holds and labor costs are controlled.

The weak points are pricing, regulation, and demand cycles. Government fee schedules can cut reimbursement. Drug companies can slow research spending. Patent litigation can also turn a normal year into a costly one.

03 Product portfolio

Two labs under one roof

Cash cow

Routine diagnostics

These are common clinical tests ordered through doctors and health systems. They help keep volume steady because patients need testing in normal care.

Growth engine

Esoteric and specialty testing

These tests are more specialized than routine blood work. They can support growth when Labcorp adds new test types or expands access.

Option

Invitae and acquired testing assets

Acquisitions can add new capabilities and revenue. The open question is how much margin lift Labcorp can get as these assets are folded into the Diagnostics platform.

Steady

Central laboratory services

This part of BLS supports drug trials by handling lab testing for biopharma customers. Q1 2026 margin improvement in BLS was tied to growth in this business.

Growth engine

Biopharma development lab services

These services help drugmakers during development. The segment is still growing, but recent organic growth has slowed, so demand needs close watching.

04 Business segments

Diagnostics still drives the company

Diagnostics78%modest
Biopharma Laboratory Services22%modest

The mix is from Q1 2026 revenue. Diagnostics made up about 78.1% of revenue, so Labcorp remains highly tied to clinical testing demand and reimbursement.

05 Risk factors

What could break the thesis

BLS demand keeps slowing

Medium impact · Medium odds

BLS organic growth fell to 3.7% in Q1 2026 after slowing in late 2025. If drugmakers cut research budgets or move less work through central labs, this segment may not give Labcorp the growth support investors expect.

We watchBLS organic growth in Q2 and Q3 2026, plus management comments on central labs and early development demand.

Ravgen appeal goes against Labcorp

High impact · Medium odds

A jury awarded Ravgen damages of $272.0 million, and later court awards brought the total above $374 million before ongoing royalties. Labcorp is appealing, but a bad final outcome would be a real cash cost.

We watchCourt updates on the Ravgen Inc. patent litigation appeal and any change in accrued liability or royalty disclosures.

PAMA cuts return in 2027

Medium impact · Medium odds

PAMA-related rate decreases were frozen for 2026 by the February 2026 spending law. The risk did not vanish. Phased-in cuts of up to 15% per year can resume in 2027.

We watchCMS clinical lab fee schedule updates and any company estimate of 2027 reimbursement pressure.

Diagnostics margin gains fade

Medium impact · Medium odds

Diagnostics is the larger segment, so margin pressure there matters most. Q1 2026 was positive, with margin rising to 16.6%, but earlier periods showed Invitae and weather could hurt profit.

We watchDiagnostics operating margin, acquisition integration costs, and management comments on Invitae synergies.

LDT regulation comes back

Medium impact · Low odds

The FDA rule for laboratory-developed tests, or LDTs, was rescinded after legal challenges. That removed an immediate cost risk. The FDA could still try a revised approach later.

We watchAny new FDA proposal or court action about regulating laboratory-developed tests as medical devices.
06 Quick answers

In one breath

What does Labcorp do?

Labcorp runs lab tests for healthcare and drug development. Its largest business is Diagnostics, which handles clinical tests ordered in patient care.

Why is BLS important if it is smaller?

BLS is about 21.9% of Q1 2026 revenue, but it gives Labcorp exposure to biopharma research spending. Slower BLS organic growth can signal softer demand from drugmakers.

What is the biggest legal risk for Labcorp?

The main legal risk is the Ravgen patent case. Ravgen has been awarded more than $374 million plus ongoing royalties, though Labcorp is appealing.